<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>培養肝細胞の3'-Me-DAB処理による細胞悪性度の増強に関する研究 第1編 3'-Me-DAB処理細胞の生物学的性状の検討</ArticleTitle>
    <FirstPage LZero="delete">151</FirstPage>
    <LastPage>163</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Syoichi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A cloned strain, CL20, which was derived from the liver of rats fed 4-dimethylaminoazobenzene had low tumor-producing capacity, but had high tumor producing capacity after treatment of the cells with 3'-Me-DAB in the presence or absence of S15 mixture. The size of tumors produced at 60 days after back-transplantation of the cells treated with 3'-Me-DAB in the presence or absence of S15 mixture was larger than that of the non-treated control cells. Similar results were obtained for the weight of tumors produced at 90 days after back-transplantation. Treatment of the cells with 3'-Me-DAB in the presence or absence of S15 mixture produced morphological changes of cells in vitro. The plating efficiency and the size of aggregates formed by rotation culture were higher in treated cells than in control cells. A few differences in growth patterns and in the resistances to the toxic effects of 3'-Me-DAB in the presence or absence of S15 mixture were found between treated and control cells. These findings suggested that cell malignancy was promoted by the treatment of 3'-Me-DAB in the presence or absence of S15 mixture.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">動物復元実験</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">3'-Me-DAB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S15 mixture</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>膠原病の肺病変に関する臨床的研究 第Ⅱ編 肺線維症の治療に関する臨床的研究</ArticleTitle>
    <FirstPage LZero="delete">141</FirstPage>
    <LastPage>150</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kaname</FirstName>
        <LastName>Ono</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The therapeutic effect of steroid hormone(STH) against pulmonary fibrosis was evaluated in 6 patients with dermatomyositis(DM), 6 with progressive systemic sclerosis(PSS), 3 with rheumatoid arthritis(RA) and 5 with idiopathic pulmonary fibrosis(IPF). Of these patients, 7 were male and 13 were female. The average age was 46.5, ranging from 24 to 66 years old. Dosage of STH varied between 10mg and 40mg/day in each patient and the mean administration period was 14 months. Clinical effects were determined using chest X-ray film, % VC, PaO(2) and direct questioning. Twelve out of 20 patients improved after STH therapy. The clinical effectiveness of STH depended on the ground disease of patients with pulmonary fibrosis; that is, STH was most effective against pulmonary fibrosis in patients with DM and less effective in patients with PSS. STH was also effective in patients with acute stage IPF, but not in patients with chronic IPF. STH seemed to be dose dependent, being more effective in patients with the high dosage of STH. Nodular shadows on chest X-ray film were more sensitive to STH therapy than reticular shadows. Moreover, % VC and PaO(2) seemed to be useful for judging the effectiveness of STH therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">膠原病</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">肺線維症</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ステロイドホルモン</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>膠原病の肺病変に関する臨床的研究 第1編 とくに肺線維症を中心とした臨床的研究</ArticleTitle>
    <FirstPage LZero="delete">131</FirstPage>
    <LastPage>140</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kaname</FirstName>
        <LastName>Ono</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pulmonary lesions appearing in chest X-ray films were studied in 24 patients with progressive systemic sclerosis(PSS), 25 with polymyositis and dermatomyositis(PM-DM), 30 with rheumatoid arthritis(RA), 37 with Hashimoto's thyroiditis(HT), 59 with Sjogren's syndrome(SS) and 18 with Behcet's syndrome(BS). Pulmonary fibrosing changes were most common in these patients. The incidence of pulmonary fibrosis in connective tissue disease was as follows: 17 patients(71%) in PSS, 16(64%) in PM-DM, 17(57%) if RA, 10(26%) in HT, 23(39%) in SS and 2(11%) in BS. Pulmonary emphysema was observed in 2 patients with SS and pulmonary infarction was observed in one patient with BS. Fibrotic changes were most severe in PSS, in which positive anti-lung antibody and involvement of the alimentary tract were ofen detected in patients with pulmonary fibrosis. Pulmonary fibrosis in DM correlated well with the titer of anti-lung antibody, but not with other laboratory findings such as anti-nuclear antibody, CH50, RF, CRP, transaminase, LDH or γ-globulin level. In RA, HT, SS and BS, there was no significant correlation between pulmonary fibrosis and the laboratory findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">膠原病</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">膠原病近縁疾患</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">肺線維症</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">間質性肺炎</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>呼吸器疾患における単球および肺胞マクロファージの走性に関する研究 第Ⅱ編 肺胞マクロファージの化学走性に関する研究</ArticleTitle>
    <FirstPage LZero="delete">115</FirstPage>
    <LastPage>129</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Sato</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cells were taken from the peripheral lung by bronchoalveolar lavage in 43 subjects including 15 patients with bronchial asthma, 11 patients with sarcoidosis, 4 patients with hypersensitivity pneumonitis, 2 patients with lung fibrosis, and 11 normal adults as controls. Chemotaxis of alveolar macrophage to zymosan activated serum was observed, using an agarose plate method. The results were as follows. 1) The chemotaxis of alveolar macrophages from healthy smokers was increased, compared to that of nonsmokers. The alveolar macrophages from smokers with bronchial asthma or sarcoidosis also showed increased chemotaxis. 2) Alveolar macrophage chemotaxis was significantly decreased in asthma patients(nonsmokers) than in healthy nonsmokers. 3) Alveolar macrophage chemotaxis in asthma patients(nonsmokers) was not influenced by the regimen of small or middle doses of glucocorticoid hormone. 4) The chemotaxis of alveolar macrophages from patients with sarcoidosis(nonsmokers) was significantly decreased, compared to that of healthy nonsmokers. 5) Alveolar macrophage chemotaxis was increased in a patient with hypersensitivity pneumonitis, and decreased in patients with lung fibrosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">肺胞マクロファージ(alveolar macrophage)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">化学走性気管支喘息(chemotaxis bronchial asthma)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">気管支肺胞洗浄法(broncho-alveolar lavage)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>呼吸器疾患における単球および肺胞マクロファージの走性に関する研究 第I編 単球の化学走性に関する研究</ArticleTitle>
    <FirstPage LZero="delete">103</FirstPage>
    <LastPage>114</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Sato</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Monocyte chemotaxis to zymosan-activated serum was observed in 51 subjects including 31 patients with bronchial asthma, 7 patients with other respiratory diseases, and 13 normal adults as controls, using an agarose plate method. The results were as follows: 1) Monocyte chemotaxis in normal subjects showed no significant difference between females and males or between smokers and nonsmokers. 2) No significant difference was observed in monocyte chemotaxis between normal subjects and patients with bronchial asthma. 3) Monocyte chemotaxis was significantly increased after asthma attacks, although middle dose of glucocorticoid hormone were administered, compared with the non-attack stage and with during an attack. 4) Monocyte chemotaxis was not affected by serum IgE levels, although random migration of monocyte was significantly decreased in asthma patients who had serum IgE more than 500 IU/ml. 5) No significant difference was present in monocyte chemotaxis between two asthma groups defined by age of onset(&lt;or≧40 years old). 6) There was no significant difference in monocyte chemotaxis between skin test positive and negative groups. 7) Small doses of glucocorticoid hormone did not affect the chemotaxis of monocytes from asthma patients. 8) Monocyte chemotaxis was decreased in 2 of 3 cases with hypersensitivity pneumonitis, and markedly increased in one patient with generalized aspergillosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">気管支喘息(bronchial asthma)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">単球(monocyte)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">化学走性(chemotaxis)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>側坐核と辺縁系発作―燃え上がり現象を用いた研究</ArticleTitle>
    <FirstPage LZero="delete">87</FirstPage>
    <LastPage>102</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Motoshi</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>An antagonistic relationship between epilepsy and psychosis has been claimed. On the other hand, abnormality of the N. accumbens is thought to be involved in schizophrenia and temporal lobe epilepsy. In order to examine the role of the N. accumbens in limbic seizure and psychosis, the following were studied: 1. Amygdaloid kindling and the functional change of the N. accumbens, 2. Accumbens kindling, 3. Functional change of limbic nuclei following the accumbens kindling, and 4. The effects of lesioning of the N. accumbens on the amygdaloid kindling. The results were as follows: 1. The amygdaloid kindling induced epileptic focus and positive transfer into the N. accumbens. 2. The kindling phenomenon was confirmed positive by repeated stimulation of the N. accumbens. Clinicoelectrographic seizure development during the N. accumbens kindling resembled that of amygdaloid kindling. The mean minimum intensities to induce afterdischarge and kindling rate were 620μA and 23days, respectively. 3. Positive transfer was found in the N. amygdala and hippocampus following the accumbens kindling. 4. Lesioning of the N. accumbens had no effect on amygdaloid seizure development, but lowered the threshold intensity to induce amygdaloid afterdischarge after kindling. It was concluded that the N. accumbens and the N. amygdala formed epileptic hyperexcitability reciprocally and that the N. accumbens had an inhibitory effect on the limbic seizure, but no effect on the developed amygdaloid kindling.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">側坐核</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">燃え上がり現象</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">辺縁系発作</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">中脳辺縁ドパミン系</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">側頭葉てんかん</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>手根溝の構築についての研究</ArticleTitle>
    <FirstPage LZero="delete">73</FirstPage>
    <LastPage>86</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mitsunobu</FirstName>
        <LastName>Kouno</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>手根部の形態学的研究は,臨床的に手根管症候群や見落され易いこの部の外傷の病態を知る上で重要であり,また手関節の運動の際に,個々の手根骨がどのような動きをするのかを検索することも運動学的に意義深いと考えられる.手根部の形態学的研究は,靱帯,腱,血管神経などの軟部組織を主体にしたものが多く,骨の構築に関するものは意外に少ない.8個の骨が形成する手根部の構築の研究はX線写真によるものが多く,その代表的なものにT.H.Bryce(1)),R.Arkless(2)),Y.Youm(3))の研究がある.これらは前後,側方2方向のX線像について,手関節の動きと骨相互の位置を研究したものである.しかし手根溝を横断面でみると,特徴的なアーチ構造を呈しており,これについての詳細な研究は,著者の渉猟する限りでは見当らないようである.また手根骨の骨梁についても個々の骨についての記載は,M.C.Hall(4))などにみられるものの手根溝を1つの構造単位として検索した研究はほとんどみられないようである.著者はこのような観点から,近年進歩した高分子化合物,硬組織薄切技術,超軟X線装置を用いて,手根溝の横断面の形状および骨梁構造について研究し考察を加えた.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">手根溝</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">骨梁構造</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">骨性構築</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">microradiography</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>シェーグレン症候群に関する臨床的研究 第二編 シェーグレン症候群の臨床像とステロイド療法に関する研究</ArticleTitle>
    <FirstPage LZero="delete">59</FirstPage>
    <LastPage>72</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Kageyama</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We analyzed the clinical and laboratory findings of 160 patients with definite Sjogren's syndrome, and examined the effect of corticosteroid therapy on these patients. One hundred and fifty nine were female, and the average age at the time of diagnosis was 46.2±12.2 years. The past histories disclosed gynecological diseases in 44 patients (29.9%) and appendicitis in 32(21.8%); 10(6.8%) with sinusitis; 10(6.8%) with pleuritis. Complaints of oral dryness and decreased saliva were common in 73.8% of patients. Failure of lacrimation, redness, "film", and increased dental caries were present in 20-30% of patients. In addition, systemic manifestations such as arthralgia, fever, Raynaud's phenomenon, and lymph node swelling were frequent. Abnormalities of Schirmer's test, gum test, histological findings of salivary glands, and of the sialogram were found in 80% of patients. Hyper γ-globulinemia was present in 81%. Anti SS-A antibody, rheumatoid factor, and total antinuclear antibodies were positive in 60-70%. Corticosteroid was effective for patients with the sicca syndrome; it relieved the symptoms of dry eye and dry mouth, and also tended to decrease the inflamation of the salivary glands. Serum γ-globulin and amylase were lower immediately after the corticosteroid treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Clinical and laboratory findings</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sjogren's syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Corticosteroid therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>シェーグレン症候群に関する臨床的研究 第一編 シェーグレン症候群における小唾液腺生検像と口腔乾燥症状との関連に関する研究</ArticleTitle>
    <FirstPage LZero="delete">51</FirstPage>
    <LastPage>58</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Kageyama</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Labial salivary gland specimens were obtained from 470 patients with sicca syndrome, collagen diseases and other diseases, and were analyzed according to the histological criteria reported by Chisholm and Mason. Abnormal findings were observed the labial salivary gland in 133(55.0%) of 242 patient with xerostomia that were significantly higher(P&lt;0.001) as compared with 64(28.1%) of 228 patients without xerostomia. The histological findings correlated well with the findings of parotid sialography(p&lt;0.001). In patients without xerostomia, abnormal histological findings were frequently observed in collagen disease; 8(13.1%) of 61 patients with rheumatoid arthritis; 17(22.7%) of 75 patients with systemic lupus erythematosus; and 9(30.0%) of 30 patients with mixed connective tissue disease. In 193 patients with abnormal findings in the salivary gland, the average age of the patient with xerostomia at biopsy was higher than that of the patients without symptoms(p&lt;0.001). Since it remains nuclear whether the patients who show abnormal findings of labial salivary gland without xerostomia have Sjogren's syndrome, or whether these histological abnormalities represent part of the basic disease process, these patients should be oberved under the term of "subclinical" Sjogren's syndrome.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Labial salivary gland biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Xerostomia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sjogren's syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>本邦に寄港中発症した外国人船員のマラリヤ</ArticleTitle>
    <FirstPage LZero="delete">45</FirstPage>
    <LastPage>49</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Kira</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masana</FirstName>
        <LastName>Ogata</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasumasa</FirstName>
        <LastName>Tongu</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Aji</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiiti</FirstName>
        <LastName>Inatomi</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Tada</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Setsuo</FirstName>
        <LastName>Suguri</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A foreign soilor who had arrived by ship from Goa, India, was found to be infected with both Plasmodium falciparum and P. vivax. Although the P. vivax was a chloroquine-resistant type, Fansidal Ⓡ was effective and the patient recovered. As it was the season for proliferation of mosquitoes in Japan, the patient was isolated so as not to become a source of secondary infection. Knowing the place where a patient with high grade fever comes from is of great help in diagnosing malaria, which is seldom seen in Japan.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Malaria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Plasmodium vivax</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">P. falciparum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chloroquine-resistant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sjögren病の病因と治療に関する研究 第2編 Sjögren病単独例に対する副腎皮質ホルモン剤の効果</ArticleTitle>
    <FirstPage LZero="delete">35</FirstPage>
    <LastPage>44</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Takaya</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The effect of prednisolone (PSL) on clinical symptoms and laboratory parameters was studied in nineteen patients with Sjögren's syndrome (SjS) without associated diseases (SjS alone). The mean initial dose of PSL was 11.7±13.0 mg/day (M±SD), and the mean maintenance dose was 6.1±3.9 mg/day. The mean duration of the treatment was 25.2±14.1 months. Fever, polyarthralgia, elevated erythrocyte sedimentation rate, and hypergamma-globlinemia were improved by the PSL treatment. However, no effect of PSL on the ocular and oral sicca symptoms including parotid enlargements, function of the exocrine glands and sialographical findings of parotid glands was observed. Neither Raynaud's phenomenon nor various autoantibodies detected in patients' sera was affected by this treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Sjögren's syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Steroid hormone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sjögren病の病因と治療に関する研究 第1編 Sjögren病患者末梢血単球の赤血球貪食能</ArticleTitle>
    <FirstPage LZero="delete">25</FirstPage>
    <LastPage>34</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Takaya</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The erythrophagocytic activity of peripheral blood monocytes in patients with Sjögren's syndrome (SjS) was investigated by using 51Cr-labelled SRBC sensitized with anti-SRBC antibody (IgG). The phagocytic activity of monocytes in patients with SjS alone was similar to that in healthy adults. On the other hand, the phagocytic activity of monocytes in patients with SjS associated with systemic lupus erythematosus or rheumatoid arthritis was lower than that in healty adults. There was no significant correlation, however, between phagocytic activity and several clinical parameters such as serum rheumatoid factor, erythrocyte sedimentation rate, serum complement level or the doses of prednisolone administered.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Sjogren's syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Erythrophagocytosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Monocytes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fc receptor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>3´-Methyl-N-benzoyloxy-MABによる培養ラット肝細胞の癌化</ArticleTitle>
    <FirstPage LZero="delete">17</FirstPage>
    <LastPage>23</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Tokiwa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shizuo</FirstName>
        <LastName>Nishizaki</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jiro</FirstName>
        <LastName>Sato</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cytotoxic effects, chromosomal aberrations and malignant transformation in a cloned rat liver cell strain(Ac2F) were examined by treatment with an active metabolite of 3'-methyl-4-dimethylaminoazobenzene(3'-Me-DAB), 3'-methyl-N-benzoyloxy-methylaminoazobenzene (3'-Me-N-benzoyloxy-MAB). The results are summarized as follows. 1) 3'-Me-N-benzoyloxy-MAB induced not only marked cytotoxic effects but also chromosomal aberrations on the cells when compared with 3'-Me-DAB. 2) The cells underwent malignant transformation at 51-53 days of culture after they had been treated three times with 6.9 ug/ml of 3'-Me-N-benzoyloxy-MAB. 3) 3'-Me-N-benzoyloxy-MAB-treated cells exhibited altered morphology, increased plating efficiency in liquid medium and increased size of aggregates in rotation culture, but not colony formation in semisolid agar medium or multinucleation by cytochalasin B. 4) These results strongly suggest that 3'-Me-N-benzoyloxy-MAB was an ultimate type carcinogen of 3'-Me-DAB.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">3´-Me-N-benzoyloxy-MAB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">培養ラット肝細胞</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">癌化</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>抗腫瘍抗体結合抗癌剤に関する研究 第1編 抗腫瘍抗体結合Neocarzinostatin(NCS-immune IgG)の補体依存細胞障害作用とcapping抑制効果</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage>15</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Sato</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In the previous paper, we reported that Neocarzinostatin (NCS) could bind covalently to rabbit anti-tumor IgG (Immune IgG) without losing its pharmacological activity. In this study, the complement dependent cytotoxicity and capping inhibition of the conjugate were evaluated. When antibody activity was measured by (3)H-TdR uptake inhibition and (51)Cr release tests in the presence of human complement, the cytotoxicity of the conjugate was significantly reduced in contrast to the antibody binding activity tested by immunofluorescence. In addition, an anti-complement immunofluorescent test showed that NCS-immune IgG fixed less complement on NALL-1 cells than immune IgG. These results indicate that complement fixing sites of NCS-immune IgG are damaged during chemical conjugation. The capping experiment demonstrated that NCS-immune IgG interfered with the capping of antigens on the NALL-1 cell surface, and that the capping inhibiting activity was almost the same degree as that of free NCS. This unique advantage of NCS-immune IgG may be useful for inhibiting the immunological escape of tumor cells from antibody attack in vivo.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Antibody-NCS conjugate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Complement dependent cytotoxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Capping inhibition</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山医学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1558</Issn>
      <Volume>94</Volume>
      <Issue>1-2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1982</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>強皮症における抗核抗体の検討</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>8</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Furuta</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Antinuclear antibodies were detected in 30 of 38 (79%) patients with scleroderma by indirect immunofluorescence using rat liver sections as a substrate. Seventeen of 30 patients who were positive for antinuclear antibodies also had antinucleolar antibodies.Antibodies to non-histone nuclear antigens were identified by double immunodiffusion in 0.45% agarose. The incidence of anti RNP antibody was 13%; anti SS-A antibody, 45%; anti SS-B antibody, 13%; anti Sm antibody, 0%; anti MU antibody, 0%; anti Scl-l antibody, 58%.Scl-1 antigen was not found in isotonic saline soluble extracts of human spleen, human liver, rabbit thymus, rat liver or Raji cell. Alternatively, the antigen was extracted from these organs with hypertonic salt solutions (0.3M, 0.6M, 1.0M, NaCl). The antigen was inactivated by heating at 37•Ž for 1 hour. It was resistant to digestion with deoxyribonuclease or ribonuclease, and was destroyed by trypsin digestion.Antibodies to Scl-1 antigen were detected in sera from 22 of 38 (58%) patients with scleroderma, 1 of 10 (10%) with sclerodermatomyositis, 1 of 26 (4%) with mixed connective tissue disease and 1 of 32 (3%) with undifferentiated connective tissue disease having anti RNP antibody. Anti Scl-1 antibody was not present in sera from 18 patients with polymyositis or dermatomyositis, 88 with systemic lupus erythematosus, 55 with rheumatoid arthritis, 44 with sicca complex or 24 with Hashimoto's thyroiditis. The patients with scleroderma had a significantly high incidence of the antibody (P&lt;0.01). The present study suggests that anti Scl-1 antibody might be a useful marker for scleroderma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">強皮症</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">抗核抗体</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">非ヒストン核</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">蛋白抗体</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">抗Scl-1抗体</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
